Proceedings of the National Academy of Sciences, Volume 123, Issue 13, March 2026. SignificanceHere, we identify a molecular pathway that drives cisplatin resistance in head and neck squamous cell carcinoma (HNSCC). The angiogenic factor angiopoietin-like 4 (ANGPTL4) engages Neuropilin1 to activate ABL1, which in turn phosphorylates and ...
PNAS published a clinical update in Research Highlights on 26 Mar 2026.
The item focuses on Targeting the ANGPTL4/NRP1/ABL1/RAD51 axis reverses cisplatin resistance by impairing DNA damage repair in head and neck cancer.
Review the original article for the full source wording and details.